Several sociodemographic, clinical, or laboratory parameters such as age, BMI, fasting plasma glucose, and HbA1c have been identified as factors capable of predicting the onset and severity of hyperglycemia in patients treated with PI3K inhibitors [12, 14]. The gene discussed is PIK3CA; the disease is Hyperglycemia.